References of "Carcinogenesis"
     in
Bookmark and Share    
Full Text
See detailEffects of HPV-16 E5, E6 and E7 Proteins on Survival, Adhesion, Migration and Invasion of Trophoblastic Cells
Boulenouar, S.; Weyn, C.; Van Noppen, M. et al

in Carcinogenesis (2010), 31(3), 473-80

Amongst high-risk human papillomaviruses (HPV), HPV-16 infection is the most prevalent causative factor for cervical cancer. Beside other mucosal targets, HPV-16 was reported to infect the placenta and to ... [more ▼]

Amongst high-risk human papillomaviruses (HPV), HPV-16 infection is the most prevalent causative factor for cervical cancer. Beside other mucosal targets, HPV-16 was reported to infect the placenta and to replicate in trophoblastic cells. Since these cells share invasive properties of tumoral cells, they represent an ideal model to investigate several oncogenic processes. In the present work, we analyzed the impacts of HPV-16 E5, E6 and E7 oncoproteins on the trophoblastic model. Our results showed that E5 impaired the viability of trophoblastic and cervical cell lines but E6 and E7, favouring cell growth, neutralised the E5 cytotoxic effect. In addition, E5 decreased the adhesiveness of trophoblastic cells to the tissue culture plastic and to endometrial cells similarly as previously described for E6 and E7. E5 and E6 plus E7 increased also their migration and their invasive properties. Cells expressing HPV-16 early proteins under the control of the LCR endogenous promoter displayed growth advantage and were also more motile and invasive compared to control cells. Interestingly, the E-cadherin was down regulated in trophoblastic cells expressing E5, E6 and E7. NF-kB and AP-1 activities were also enhanced. In conclusion, HPV-16 early proteins enhanced trophoblastic growth and intensify the malignant phenotype by impairing cell adhesion leading to increased cellular motile and invasive properties. HPV-16 E5 participated, with E6 and E7, in these changes by impairing Ecadherin expression, a hallmark of malignant progression. [less ▲]

Detailed reference viewed: 35 (5 ULg)
Full Text
See detailReduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors
Maillard, Catherine ULg; Bouquet, C.; Petitjean, Marie et al

in Carcinogenesis (2008), 29(11), 2236-2242

Plasminogen activator inhibitor-1 is known to play a paradoxical positive role in tumor angiogenesis, but its contribution to metastatic spread remains unclear. We studied the impact of PAI-1 deficiency ... [more ▼]

Plasminogen activator inhibitor-1 is known to play a paradoxical positive role in tumor angiogenesis, but its contribution to metastatic spread remains unclear. We studied the impact of PAI-1 deficiency in a transgenic mouse model of ocular tumors originating from retinal epithelial cells and leading to brain metastasis (TRP-1/SV40 Tag mice). PAI-1 deficiency did not affect primary tumor growth or vascularization, but was associated with a smaller number of brain metastases. Brain metastases were found to be differentially distributed between the two genotypes. PAI-1-deficient mice displayed mostly secondary foci expanding from local optic nerve infiltration, whereas wild-type animals displayed more disseminated nodules in the scissura and meningeal spaces. SuperArray GEArray analyses aiming to detect molecules potentially compensating for PAI-1 deficiency demonstrated an increase in fibroblast growth factor-1 (FGF-1) gene expression in primary tumors, which was confirmed by RT-PCR and western blotting. Our data provide the first evidence of a key role for PAI-1 in a spontaneous model of metastasis, and suggest that angiogenic factors, such as FGF-1, may be important for primary tumor growth and may compensate for the absence of PAI-1. They identify PAI-1 and FGF-1 as important targets for combined anti-tumor strategies. [less ▲]

Detailed reference viewed: 79 (10 ULg)
See detailRat Gap Junction Connexin-30 Inhibits Proliferation of Glioma Cell Lines
Princen, Frederic; Robe, Pierre ULg; Gros, D. et al

in Carcinogenesis (2001), 22(3), 507-13

Connexins, the structural components of gap junctions, control cell growth and differentiation and are believed to belong to a family of tumour suppressor genes. Studies on connexin localization in brain ... [more ▼]

Connexins, the structural components of gap junctions, control cell growth and differentiation and are believed to belong to a family of tumour suppressor genes. Studies on connexin localization in brain showed that several of these proteins were expressed in distinct compartments of the brain in a cell-type specific manner, indicating that different gap junctions play specific roles in the physiology of the mammalian brain. In this report, we first cloned rat connexin-30 cDNA from brain and showed that it was expressed in long-term primary culture of rat astrocytes. In order to examine the potential role of connexin-30 in tumour cell proliferation, we transfected the connexin-30 cDNA into two rat glioma cell lines (9L and C6) which have lost its expression. Transfected clones adequately expressed membrane-bound connexin-30 protein. Connexin-30-expressing clones showed slower growth, lower DNA synthesis and reduced proliferation in soft agar as compared with the parental and control cells. We concluded that connexin-30 may also probably be considered as a tumour suppressor in rat gliomas. [less ▲]

Detailed reference viewed: 29 (0 ULg)
See detailRelease of N2,3-ethanoguanine from haloethylnitrosourea-treated DNA by Escherichia coli 3-methyladenine DNA glycosylase II
Habraken, Yvette ULg; Carter, C.; Sekiguchi, M. et al

in Carcinogenesis (1991), 12(10), 1971-1973

Detailed reference viewed: 1 (0 ULg)
See detailFormation of N2,3-ethanoguanine in DNA after in vitro treatment with the therapeutic agent, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea
Habraken, Yvette ULg; Carter, C.; Kirk, M. et al

in Carcinogenesis (1990), 11(2), 223-228

Detailed reference viewed: 2 (0 ULg)
See detailDevelopment of monoclonal antibodies recognizing 7-(2-hydroxyethyl)guanine and imidazole ring-opened 7-(2-hydroxyethyl)guanine.
Young, T. L.; Habraken, Yvette ULg; Ludlum, D. et al

in Carcinogenesis (1990), 11

Detailed reference viewed: 2 (0 ULg)
See detailRelationship of Serum Selenium Levels to Tumor Activity in Acute Non-Lymphocytic Leukemia
Beguin, Yves ULg; Bours, Vincent ULg; Delbrouck, J. M. et al

in Carcinogenesis (1989), 10(11), 2089-91

Serum selenium (Se) levels were measured before, during and after high-dose induction chemotherapy in 70 patients with acute non-lymphocytic leukemia (ANLL). Pre-treatment serum Se levels were lower in ... [more ▼]

Serum selenium (Se) levels were measured before, during and after high-dose induction chemotherapy in 70 patients with acute non-lymphocytic leukemia (ANLL). Pre-treatment serum Se levels were lower in patients than in controls (0.082 +/- 0.033 micrograms/ml versus 0.097 +/- 0.035 micrograms/ml, P less than 0.01). Pretreatment serum Se correlated inversely with the absolute peripheral blast cell count (R = -0.62, P less than 0.001) and other measurements of the tumor burden. Seven days after the initiation of chemotherapy, serum Se increased significantly in proportion to the initial tumor burden (P less than 0.01). Thereafter, serum Se levels remained essentially normal in patients entering a complete remission while decreasing gradually in failures. In conclusion, these data do not lend support to the hypothesis that a low selenium status enhances the risk of developing ANLL, but indicate that serum Se levels in patients with acute leukemia are mostly dependent on tumor activity. [less ▲]

Detailed reference viewed: 26 (17 ULg)
See detailRelease of the chloroethyl ethyl sulfide-modified DNA bases by bacterial 3-methyladenine DNA glycosylase I and II
Habraken, Yvette ULg; Ludlum, David

in Carcinogenesis (1989), 10(3), 489-492

Detailed reference viewed: 1 (0 ULg)